This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

No Rest Yet for Neurocrine

Neurocrine Biosciences (NBIX) said Thursday it might need to conduct more clinical or pre-clinical trials on safety issues to secure approval of its insomnia drug Indiplon.

The company said a delay in getting U.S. regulatory approval probably will cause it to amend its financial guidance during its second-quarter Webcast, although Neurocrine provided no details.

The San Diego, Calif.-based company provided the update after markets had closed, saying it had prepared a response to questions that the Food and Drug Administration posed last month. On May 15, the agency granted conditional approval for a quick-release version of Indiplon, but the agency rejected an application for an extended-release version.

If the agency requires more clinical trials, Neurocrine would suffer a major setback -- and an expensive, time-consuming delay -- in its effort to compete with drugs such as Ambien CR from Sanofi-Aventis (SNY) and Lunesta from Sepracor (SEPR).

Neurocrine has enlisted Pfizer (PFE) as its marketing partner.

When Neurocrine reported the FDA's decision last month , the stock was crushed. The agency's decision surprised both company management and Wall Street analysts. At the time, Gary A. Lyons, the chief executive, said he believed the FDA action represented a "short-term setback."

But on Thursday, Neurocrine suggested there might be a longer delay. Neurocrine said it has requested a meeting with the FDA to "help the company determine plans in moving forward."

For the immediate-release version of Indiplon, Neurocrine said the FDA wanted it to reanalyze data from some pre-clinical and clinical studies. "The FDA also requested reexamination of the safety analysis for the elderly population," the company said. "The FDA may require additional clinical and/or pre-clinical safety data."

As for the extended-release version, Neurocrine said "additional clinical data will likely be required." The FDA asked the company to reanalyze certain safety and efficacy data. The FDA "also questioned the sufficiency of the company's objective sleep-maintenance clinical data" because most tests were conducted with dosage levels higher than what Neurocrine is seeking in its application, Neurocrine said.

In regular trading Thursday, Neurocrine's stock closed up $1.29, or 7.1%, at $19.37. But after hours, the stock fell 90 cents.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs